ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
Assessing the Impact of Antidepressants on Cancer Treatment: A Retrospective Analysis of 14 Antineoplastic Agents.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rates of depression among patients with cancer have increased, illustrating the importance of mental health care during treatment. This study sought to identify antidepressants with boxed warnings for increased suicidal risk and known to have drug-drug interactions. Methods: This retrospective analysis used the US Department of Defense Cancer Registry, Comprehensive Ambulatory/Professional Encounter Record, and Pharmacy Data Transaction Service databases. Patients with cancer were identified, and data collected included patient diagnoses and dispensed medications. Medications were divided into groups based on the pharmacy database therapeutic codes. Results: This analysis identified 2210 patients with 2104 documented diagnoses, 2113 recorded prescriptions treated with 14 antineoplastic agents. Breast, lung, testicular, endometrial, and ovarian were the most common cancers among the 51 types treated. Of the 2113 patients with recorded prescriptions, 1297 patients (61.4%) received 109 cancer medications, including 96 different antineoplastics; 750 (35.5%) patients were prescribed 17 different types of antidepressants. In addition, 1089 unique prescriptions were filled (8 medications prescribed for ≥ 1000 patients). Patients who took antidepressants had more diagnosed health issues and received more prescription medications. The mean number of prescriptions dispensed in patients prescribed antidepressants vs those not prescribed antidepressants showed a significant difference ( Conclusions: The study provides a comprehensive overview of noncancer medication use in the Military Health System during systemic cancer treatment, specifically the use of antidepressants from 2003 to 2022, and highlights potential drug interactions that may affect treatment outcomes. Future research should prioritize the analysis of drug-drug interactions between cancer and noncancer drugs with antidepressants.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.